Noxxon Pharma AG of Germany has started a Phase 2a study of an oligonucleotide-based drug in patients with multiple myeloma, a disease that accounts for about 1% of all cancers. The 28-patient, multi-center study is being conducted in Europe. ---Subscribe to MedNous to access this article--- Company News Clinical Research
